To study the effect of homoeopathic preparation of Hydrastis canadensis 30C and individualised homoeopathic medicine on Non alcoholic fatty liver disease

Phytochemical analysis of Hydrastis canadensis mother tincture and ascertaining effectiveness of its 30C dilution in comparison to individualised homoeopathic medicine in the treatment of Non-alcoholic fatty liver disease with respect to Liver Function Test parameters: An open label Randomised Clinical Trial - Nil

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2023/07/055077

Enrollment

Registered

2023-07-11

Start date

Unknown

Completion date

Unknown

Last updated

2023-07-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: K760- Fatty (change of) liver, not elsewhere classified

Interventions

Intervention1: Hydrastis canadensis 30C and individualised homoeopathic medicine: Twoâ??Four globules of Hydrastis canadensis 30C once in a day for two-month and one dose in alternative days for next

Eligibility

Inclusion criteria

Inclusion criteria: Confirmed Diagnosis of NAFLD established by ultrasound There is no significant alcohol consumption There are no competing aetiologies for hepatic steatosis There are no co existing causes for chronic liver disease Raised LFT (Liver enzymes rising (ASTâ?? >â??38, ALTâ?? >â??40) Providing written informed consent to participate

Exclusion criteria

Exclusion criteria: Absence of regular or excessive use of alcohol (more than 20 gram per day in men and 10 gram in female). History of bowel surgery, Bariatric surgery or undergoing evaluation for bariatric surgery for obesity, extensive small bowel resection or orthotopic liver transplants. History of other chronic liver disease (Viral hepatitis B or C, autoimmune hepatitis, cholestatic and metabolic liver diseases) and hemochromatosis. Known case of cirrhosis Known case of Hypothyroidism History of myopathies or evidence of active muscle disease. History of bladder disease and /or haematuria or has haematuria except due to UTI. Pregnant women, Lactating women & paediatric age group ( Uncontrolled Diabetes, Hypertension, Mental illness or depression, kidney or heart disease Patients who are too sick for consultation and not willing to cooperate Unwilling to take part and not giving consent to join the study

Design outcomes

Primary

Measure	Time frame
Total bilirubin, ALT, AST, Albumin: Globulin ratioTimepoint: All the parameters will be assessed at baseline after 2 months & after 4 months	—

Secondary

Measure	Time frame
USG (whole abdomen) alkaline phosphataseTimepoint: Alkaline phosphatase will be assessed baseline after 2 months & USG (whole abdomen) will be assessed at baseline & after 4 months.	—

Countries

India

Contacts

Public ContactDr Purnima Kadyan

National Institute of Homeopathy

Drrajanih@gmail.com9163955737

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026